研究者詳細 - 石川　哲也

論文 - 石川　哲也

分割表示 238 件中 61 - 80 件目／全件表示 >>

Immunoregulation of hepatitis B virus infection -rationale and clinical application- 招待有り

ISHIKAWA Tetsuya

Nagoya J Med Sci 74 巻頁： 217-232 2012年8月

担当区分：筆頭著者記述言語：英語

Hepatitis B virus (HBV) is susceptible to the cellular immune responses, especially to the signal of interferon (IFN)-g. The action of IFN-g is pleiotropic, and causes downregulation of HBV in protein, RNA, and possibly DNA levels. Therefore, therapeutic vaccination to induce cellular immune responses to HBV is a promising approach for controlling chronic HBV infection. A number of clinical trials with this approach have been conducted to date, however, they have not been as successful as initially expected. T-cell exhaustion induced by the excessive HBV antigens caused by persistent infection is thought to be one of the main causes of poor responses to therapeutic vaccination. In this review, the mechanisms behind immunoregulation of HBV replication and immunodysfunction during chronic HBV infection are summarized, and novel approaches to improve the efficacy of therapeutic vaccination, from basic research to clinical trials, are introduced.

機能性胃疾患診療における不安抑うつスコアの有用性と機能性胃疾患の発症および増悪因子としての心配性の関与について

洪繁、松浦俊博、木村宏之、石川哲也、京兼和宏、山田理

消化器内科 55 巻 ( 1 ) 頁： 42-49 2012年7月

記述言語：日本語掲載種別：研究論文（学術雑誌）

HADS（Hospital Anxiety Depression Scale）スコアに本人の主観的性格分類（楽天的か心配性か）を組み合わせて解析することで、機能性胃腸症発症、増悪と心配性の性格の関わりについて解析した。職域検診を受診した健常者の解析からは、心配性の性格とHADSスコアが正に相関していた。更に、機能性胃腸症患者では、うつ病で治療中の患者と同様に心配性の患者の割合が非常に高く、患者の心配性の性格が機能性胃腸症発症及び増悪因子であることが疑われた。機能性胃腸症の診療においては、多くの患者が過度に心配性であり、胃腸症状の出現により更に心配性の度合いが高じていることを考慮し、患者の不安を取り除く診療を行うことが、患者の愁訴を減少させ、治療満足度を向上させる方法であると考えられる。

瀉血による慢性肝炎の進展予防

伊東和樹, 石川哲也

medicina 48 巻 ( 7 ) 頁： 1176-1178 2011年7月

今月の主題内科疾患の予防戦略消化器疾患の予防戦略瀉血による慢性肝炎の進展予防

伊東和樹, 石川哲也

medicina 48 巻 ( 7 ) 頁： 1176 - 1178 2011年7月

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. 査読有り

HAYASHI Kazuhiko, KATANO Yoshiaki, HONDA Takashi, ISHIGAMI Masatoshi, ITOH Akihiro, HIROOKA Yoshiki, ISHIKAWA Tetsuya, NAKANO Isao, YOSHIOKA Kentaro, TOYODA Hidenori, KUMADA Takashi, GOTO Hidemi

Liver Int 頁： 1359-1365 2011年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Background and aims: Mutations in the core and NS5A region of hepatitis C virus (HCV) genotype 1b have been associated with response to interferon (IFN) therapy. Genome-wide association studies have revealed that the singlenucleotide polymorphism (SNP) of interleukin 28B (IL28B) contributes to IFN response. The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the core and NS5A region affect the response to IFN therapy. Methods: A total of 299 patients (157 men, 142 women; mean age, 55.910.3 years) infected with HCV genotype 1b were studied. The fibrosis stage was diagnosed as F0 (n = 23), F1 (n = 121), F2 (n = 62), F3 (n = 32) and F4 (n = 7) by liver biopsy. Results: Of the 299 patients, 138 achieved sustained virological response (SVR). On univariate analysis, predictors of SVR were age o60 years, male gender, higher platelet count, lack of fibrosis, non-Q at core 70, mutant-type interferon sensitivitydetermining region (ISDR) and IL28B genotype TT. The factors related to SVR on multivariate analysis were IL28B (P = 0.0001), fibrosis (P = 0.0111) and mutations in the core region70 (P = 0.0267) and ISDR (P = 0.0408). The best SVR was achieved in patients with non-Q70, mutant-type ISDR and T allele (74.5%), and the worst was achieved in patients with Q70, wild-type
ISDR and G allele (8.1%). Conclusions: The SNP of IL28B and mutations in the core region and NS5A are associated with IFN responsiveness. Both host and viral factors might be useful for predicting IFN response.

DOI： 10.1111/j.1478-3231.2011.02571.x.

バンコマイシン投与によって難治性肝性脳症が改善し肝細胞癌に対する肝動脈化学塞栓療法が可能となった1例

葛谷貞二, 竹田欽一, 宇都宮節夫, 多賀雅浩, 川田登, 池田誉, 今井則博, 水谷佳貴, 広瀬健, 石川哲也

癌と化学療法 38 巻 ( 6 ) 頁： 995 - 1001 2011年6月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：(株)癌と化学療法社

症例は80歳、男性。C型肝硬変、肝細胞癌で通院していた。2007年秋ごろから肝性脳症を繰り返すようになり、頻回の外来通院と入院加療を必要とした。肝予備能の低下により、肝細胞癌に対する治療は不可能となった。肝性脳症に対して緩下剤、ラクツロース、カナマイシン内服などの投与を行ったが、脳症のコントロールは困難であった。血中アンモニア値は130μg/dL前後で、時に200μg/dL以上となった。12月よりバンコマイシン内服(0.5g/回、3日に1回投与)を追加したところ、アンモニア値は速やかに50μg/dL低下となり、意識レベルの正常化、ADL、QOLの改善など著明な効果が得られた。バンコマイシン内服開始3ヵ月後には、Child C(10点)からChild B(7点)と肝予備能も改善、肝細胞癌に対し肝動脈化学塞栓療法が可能となった。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J00296&link_issn=&doc_id=20110629470023&doc_link_id=%2Fab8gtkrc%2F2011%2F003806%2F025%2F0995-0997%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2011%2F003806%2F025%2F0995-0997%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Liver stiffness in extrahepatic cholestasis correlates positively with bilirubin and negatively with alanime aminotransferase

HARATA Masao, HASHIMOTO Senju, KAWABE Naoto, NITTA Yoshifumi, MURAO Michihito, NAKANO Takuji, ARIMA Yuko, SHIMAZAKI Hiroaki, ISHIKAWA Tetsuya, OKUMURA Akihiko, ICHINO Naohiro, OSAKABE Keisuke, NISHIKAWA Toru, YOSHIOKA Kentaro

Hepatology research : the official journal of the Japan Society of Hepatology 41 巻 ( 5 ) 頁： 423 - 429 2011年5月

沈降型B型肝炎ワクチン招待有り

石川哲也

肝胆膵 61 巻 ( 6 ) 頁： 1088-1094 2010年12月

Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. 査読有り国際誌

Hiromitsu Iwata, Yuta Shibamoto, Chisa Hashizume, Yoshimasa Mori, Tatsuya Kobayashi, Naoki Hayashi, Katsura Kosaki, Tetsuya Ishikawa, Teiji Kuzuya, Setsuo Utsunomiya

Technology in cancer research & treatment 9 巻 ( 6 ) 頁： 619 - 27 2010年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

www.tcrt.org The purpose of this study was to evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for primary and metastatic liver tumors using the Novalis image-guided radiotherapy system. After preliminarily treating liver tumors using the Novalis system from July 2006, we started a protocol-based study in February 2008. Eighteen patients (6 with primary hepatocellular carcinoma and 12 with metastatic liver tumor) were treated with 55 or 50 Gy, depending upon their planned dose distribution and liver function, delivered in 10 fractions over 2 weeks. Four non-coplanar and three coplanar static beams were used. Patient age ranged from 54 to 84 years (median: 72 years). The Child-Pugh classification was Grade A in 17 patients and Grade B in 1. Tumor diameter ranged from 12 to 35 mm (median: 23 mm). Toxicities were evaluated according to the Common Terminology Criteria of Adverse Events version 4.0, and radiation-induced liver disease (RILD) was defined by Lawrence's criterion. The median follow-up period was 14.5 months. For all patients, the 1-year overall survival and local control rates were 94% and 86%, respectively. A Grade 1 liver enzyme change was observed in 5 patients, but no RILD or chronic liver dysfunction was observed. SBRT using the Novalis image-guided system is safe and effective for treating primary and metastatic liver tumors. Further investigation of SBRT for liver tumors is warranted. In view of the acceptable toxicity observed with this protocol, we have moved to a new protocol to shorten the overall treatment time and escalate the dose.

PubMed

researchmap

Ability of IDO to attenuate liver injury in α-galactosylceramide- induced hepatitis model 査読有り

Hiroyasu Ito, Masato Hoshi, Hirofumi Ohtaki, Ayako Taguchi, Kazuki Ando, Tetsuya Ishikawa, Yosuke Osawa, Akira Hara, Hisataka Moriwaki, Kuniaki Saito, Mitsuru Seishima

Journal of Immunology 185 巻 ( 8 ) 頁： 4554 - 4560 2010年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：AMER ASSOC IMMUNOLOGISTS

IDO converts tryptophan to L-kynurenine, and it is noted as a relevant molecule in promoting tolerance and suppressing adaptive immunity. In this study, we examined the effect of IDO in α-galactosylceramide (α-GalCer)-induced hepatitis. The increase in IDO expression in the liver of wild-type (WT) mice administered α-GalCer was confirmed by real-time PCR, Western blotting, and IDO immunohistochemical analysis. The serum alanine aminotransferase levels in IDO-knockout (KO) mice after α-GalCer injection significantly increased compared with those in WT mice. 1-Methyl-D-tryptophan also exacerbated liver injury in this murine hepatitis model. In α-GalCer-induced hepatitis models, TNF-α is critical in the development of liver injury. The mRNA expression and protein level of TNF-α in the liver from IDO-KO mice were more enhanced compared with those in WT mice. The phenotypes of intrahepatic lymphocytes from WT mice and IDO-KO mice treated with α-GalCer were analyzed by flow cytometry, and the numbers of CD49b+ and CD11b+ cells were found to have increased in IDO-KO mice. Moreover, as a result of the increase in the number of NK cells and macrophages in the liver of IDO-KO mice injected with α-GalCer, TNF-α secretion in these mice was greater than that in WT mice. Deficiency of IDO exacerbated liver injury in α-GalCer-induced hepatitis. IDO induced by proinflammatory cytokines may decrease the number of TNF-α-producing immune cells in the liver. Thus, IDO may suppress overactive immune response in the α-GalCer-induced hepatitis model. Copyright © 2010 by The American Association of Immunologists, Inc.

DOI： 10.4049/jimmunol.0904173

Role of tumor necrosis factor-α in acute hepatitis B virus infection

Ito Hiroyasu, Ando Kazuki, Ishikawa Tetsuya, SEISHIMA Mitsuru

炎症・再生 : 日本炎症・再生医学会雑誌 = Inflammation and regeneration 30 巻 ( 5 ) 頁： 445 - 450 2010年9月

PEG後栄養管理中の義歯誤嚥に対しネット鉗子とオーバーチューブを用い安全に異物除去が可能であった1例査読有り

綾田穣, 堀田直樹, 中野達徳, 内村正史, 花井恵美, 伊藤陽子, 徳永有姫, 吉田篤生, 石川哲也, 増子和郎

在宅医療と内視鏡治療 14 巻 ( 1 ) 頁： 46-51 2010年9月

著明な肝障害を伴ったプロトポルフィリン症の1例査読有り

嶋崎宏明, 有馬裕子, 中野卓二, 村尾道人, 新田佳史, 原田雅生, 川部直人, 橋本千樹, 長野健一, 石川哲也, 奥村明彦, 林和彦, 片野義明, 黒田誠, 吉岡健太郎

肝臓 51 巻 ( 4 ) 頁： 175 - 182 2010年4月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人日本肝臓学会

症例は29歳男性．小児期より光線過敏があった．父方の祖父，弟にも光線過敏を認める．2001年11月肝障害のため他院に入院し，プロトポルフィリン症（EPP）と診断され，肝生検では軽度線維化と色素沈着をみとめた．2005年8月腹痛，食欲不振，黄疸，肝障害のため同院に再入院した．肝生検では広範な線維化，多数の色素沈着をみとめた．2006年11月腹痛，食欲不振，便秘，微熱，黄疸のため当院に第1回目の入院をした．赤血球プロトポルフィリン13776 μg/dl ，ALT 287 IU/L，総ビリルビン5.1 mg/dl であった．2007年5月に同様の症状にて第2回目の入院をした．2008年8月に同様の症状にて第3回目の入院をし，肝不全が進行し11月死亡した．EPPは稀な遺伝性疾患であり，肝不全にて死亡する患者は多くない．しかし重症の肝障害の治療法としては肝移植しかなく，適切な時期に肝移植を考慮すべきと思われる．

DOI： 10.2957/kanzo.51.175

Scopus

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2010194025

MUC1標的免疫細胞療法とGemcitabineとの併用が著効した膵頭部多発癌肝転移の1例査読有り

今井則博, 竹田欽一, 宇都宮節夫, 多賀雅浩, 川田登, 池田誉, 水谷佳貴, 広瀬健, 石川哲也, 吉田松年

癌と化学療法 37 巻 ( 3 ) 頁： 527-529 2010年3月

B型肝炎に対する免疫療法招待有り

石川哲也

medicina 47 巻 ( 3 ) 頁： 487-490 2010年3月

[A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy]. 査読有り

Norihiro Imai, Kinichi Takeda, Setsuo Utsunomiya, Masahiro Taga, Noboru Kawata, Takashi Ikeda, Yoshitaka Mizutani, Ken Hirose, Tetsuya Ishikawa, Shonen Yoshida

Gan to kagaku ryoho. Cancer & chemotherapy 37 巻 ( 3 ) 頁： 527 - 9 2010年3月

記述言語：日本語掲載種別：研究論文（学術雑誌）

A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.

PubMed

researchmap

Role of tumor necrosis factor-.ALPHA. in acute hepatitis B virus infection

Ito Hiroyasu, Ando Kazuki, Ishikawa Tetsuya, Seishima Mitsuru

Inflammation and Regeneration 30 巻 ( 5 ) 頁： 445 - 450 2010年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：日本炎症・再生医学会

Tumor necrosis factor (TNF)-α is one of the most important factors in HBV infection and HBV infection-related diseases. Although TNF-α is critical and beneficial in HBV clearance, the liver injury is progressed by the up-regulation of TNF-α production. Taken together, TNF-α contribute to the cure and increase of severity in acute hepatitis caused by HBV. It is very important to understand the role of TNF-α, which has two-wedge sword in HBV infection, and the mechanism of TNF-α production. This review briefly overviews up to date about the role of TNF-α in HBV-induced liver injury and HBV clearance, including our results achieved recently.

DOI： 10.2492/inflammregen.30.445

Interaction between LPS-induced NO production and IDO activity in mouse peritoneal cells in the presence of activated Va14 NKT cells. 査読有り

Ohtaki H, Ito H, Ando K, Ishikawa T, Hoshi M, Tanaka R, Osawa Y, Yokochi T, Moriwaki H, Saito K, Seishima M.

Biochem Biophys Res Com 389 巻 ( 2 ) 頁： 229-234 2009年11月

BSCガストロストミーシステムを用いた胃瘻交換時における患者に与える影響についての検討

綾田穣, 堀田直樹, 中野達徳, 鮫島庸一, 吉田篤生, 花井恵美, 伊藤陽子, 徳永有姫, 石川哲也, 増子和郎

在宅医療と内視鏡治療 13 巻 ( 1 ) 頁： 19 - 24 2009年9月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：PEG・在宅医療研究会

BSCガストロストミーシステム:BSC gastrostomy system(以下BSCGSと略す)は、ガイドワイヤーを用いずに胃瘻造設後のカテーテル交換を行うことができるバンパータイプ・ボタン型カテーテルキットである。今回BSCGSに改良が加えられたため、交換に要する時間や、バイタルサインの変化について、ガイドワイヤーを用いる同タイプのキットとの比較検討を行った。BSCGSでは、有意に交換時間が短縮され(p<0.01)、バイタルサインの変化に有意差は認めず、有用かつ安全と考えられた。(著者抄録)

researchmap

Inflammatory cytokines modulate chemokine production patterns of HepG2 cells toward initially inclined direction. 査読有り

Ohashi T, Tanabe J, Ishikawa T, Okumura A, Sato K, Ayada M, Hotta N, Kuzuya K, Ito H, Nakao H, Yoneda M, Kakumu S.

Hepatol Res 39 巻 ( 5 ) 頁： 510-519 2009年5月

　前のページ - 次のページ　

<石川 哲也>

論文 - 石川 哲也

<石川　哲也>

論文 - 石川　哲也